-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*It is only for medical professionals to read.
Refer to a summary of the key points of the application of intestinal selective biologics, absolutely dry
.
In July 2021, the highly anticipated "Expert Suggestions for the Treatment of Inflammatory Bowel Disease with Biological Agents" [1] (hereinafter referred to as "Expert Suggestions") was officially published in the Chinese Journal of Digestion
.
As the first biologics expert suggestion in the field of inflammatory bowel disease (IBD) in China, it gave a detailed introduction to the standardized use of different biological agents
.
Among them, the only intestinal-selective biological agent, veldrizumab, is also included
.
Verdrizumab is a recombinant humanized IgG1 monoclonal antibody that blocks the binding of α4β7 integrin to the mucosal address cell adhesion molecule 1 (MAdCAM-1) expressed by intestinal vascular endothelial cells, thereby preventing T lymphocytes from The blood vessels migrate to the intestinal mucosa, reducing local inflammation in the intestine
.
Next, I will use a picture to interpret the main points of its clinical application, it is recommended to collect! Approval number: VV-MEDMAT-58042 Approval date: November 2021 Expiration date: November 2023 Statement: Only for medical and health professionals to understand information
.
Such information cannot replace professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice
.
If such information is used for purposes other than understanding the information, this site and the author shall not bear the relevant responsibilities.
This article is only used to provide scientific information to medical professionals, and does not represent the position of the platform
Refer to a summary of the key points of the application of intestinal selective biologics, absolutely dry
.
In July 2021, the highly anticipated "Expert Suggestions for the Treatment of Inflammatory Bowel Disease with Biological Agents" [1] (hereinafter referred to as "Expert Suggestions") was officially published in the Chinese Journal of Digestion
.
As the first biologics expert suggestion in the field of inflammatory bowel disease (IBD) in China, it gave a detailed introduction to the standardized use of different biological agents
.
Among them, the only intestinal-selective biological agent, veldrizumab, is also included
.
Verdrizumab is a recombinant humanized IgG1 monoclonal antibody that blocks the binding of α4β7 integrin to the mucosal address cell adhesion molecule 1 (MAdCAM-1) expressed by intestinal vascular endothelial cells, thereby preventing T lymphocytes from The blood vessels migrate to the intestinal mucosa, reducing local inflammation in the intestine
.
Next, I will use a picture to interpret the main points of its clinical application, it is recommended to collect! Approval number: VV-MEDMAT-58042 Approval date: November 2021 Expiration date: November 2023 Statement: Only for medical and health professionals to understand information
.
Such information cannot replace professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice
.
If such information is used for purposes other than understanding the information, this site and the author shall not bear the relevant responsibilities.
This article is only used to provide scientific information to medical professionals, and does not represent the position of the platform
